eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..
"smoking and drinking � giving these kids a little bit longer to make good decisions in their lives � i'm all for that," bruschi said.. the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe..